NEW YORK (360Dx) – German diagnostics firm Sphingotec is using proceeds from a €20 million ($23 million) funding round announced last week to commercialize automated point-of-care versions of its biomarker tests proenkephalin (penKid) and adrenomedullin (bio-ADM).
The tests are intended for monitoring kidney function (penKid) and endothelial dysfunction (bio-ADM) to identify intensive care and emergency department patients at risk of heart failure.